Transient bevacizumab (avastin)-induced alterations in rat eyes.
OBJECTIVE
To study the histopathological, biochemical and functional effects of intravitreal bevacizumab on the rat eye, with special emphasis on its immediate pro-inflammatory features eventually associated with cellular oxidative burden.


METHODS
Histopathological evaluation was performed 24 h, 1 and 4 weeks after bevacizumab (75 microg/rat eye) or saline intravitreal injection, as well as biochemical analysis of oxidative stress-related markers and electroretinograms.


RESULTS
Bevacizumab induces a transient inflammatory reaction together with a modification of the b-wave amplitude and latency of the electroretinogram. No changes were observed in any of the oxidative stress markers studied at any time after injection.


CONCLUSIONS
Intravitreal bevacizumab injection per se generates an immediate, transient and mild inflammation of the rat eye, which is not associated with oxidative stress in ocular tissues.
Sancho-Tello
María
M
Fundación Oftalmológica del Mediterráneo, Universidad CEU-Cardenal Herrera, Valencia, España.
Johnsen-Soriano
Siv
S
Muriach
María
M
Bosch-Morell
Francisco
F
Díaz-Llopis
Manuel
M
Palacios-Pozo
Elena
E
Navea
Amparo
A
Romero
Francisco Javier
FJ
D000704:Analysis of Variance; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002452:Cell Count / Q000379:methods; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004596:Electroretinography / Q000379:methods; D005123:Eye / Q000187:drug effects*; D005979:Glutathione Peroxidase / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009799:Ocular Physiological Phenomena / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D011930:Reaction Time / Q000187:drug effects; D013053:Spectrophotometry / Q000379:methods; D013997:Time Factors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D008315:Malondialdehyde; D005979:Glutathione Peroxidase